Join Grace for a presentation exploring the ways artificial intelligence (AI) and machine learning (ML) are transforming API development. Discover how we can help bring your small molecule program to market with fewer delays, less scale‑up risk and greater regulatory confidence. Following the presentation, join us for a networking reception.
As a small molecule CDMO, Grace Fine Chemicals Manufacturing Services (FCMS) partners with biotechs and pharma companies to overcome complex chemistry challenges, seamlessly scale up and navigate every phase from development to commercial manufacturing.
Register for this free event hosted at the MassBioHub in Cambridge, MA on Tuesday, May 19 from 5-8 p.m
Who should attend:
- Biotech and pharma leaders
- CMC consultants
- Pharmaceutical companies advancing small‑molecule development programs and evaluating CDMO partners for commercialization
Our presentation will explore:
- How AI and ML can help optimize process and analytical development to improve outcomes and reduce risk
- Where AI can deliver real impact, including yields, impurity reduction, and cost savings
- Our collaboration with Molecule.one for AI-powered retrosynthetic analysis for small molecules and peptide building blocks
- The capabilities of our two integrated U.S. sites, located in South Haven, MI and Tyrone, PA, to help with scale-up and technology transfer, as well as ensure security of supply
When you partner with Grace FCMS, we’ll work together to:
- Tackle complex chemistry challenges
- Scale confidently from lab to commercial manufacturing
- Identify, characterize and control impurities
- Develop robust processes and technical risk assessments
- Build agile project teams that offer direct access to our technical and analytical experts
- Ensure seamless tech transfer within our kilo lab, pilot plant and commercial equipment
Meet your presenter:
Dr. Robert Hughes
Dr. Robert Hughes is an R&D Fellow at Grace, where he leads the custom pharma technical development effort as part of the Fine Chemicals Manufacturing Services (FCMS) business. He has worked at the South Haven, Mich., site since 2007. Over his 27-year career in the pharmaceutical industry, he has held numerous scientific positions at Roche Colorado, Pfizer, and Boehringer Ingelheim. He holds a bachelor’s degree in chemistry from Northern Michigan University and a doctorate in organic chemistry from Wayne State University, which was followed by a postdoctoral position at Colorado State University.